Temasek and Kaitai Capital led a USD35m pre-Series B2 for Lupeng Pharmaceutical, a China-based clinical-stage drug developer for cancer treatment, with follow-on from Lilly Asia Ventures, Fontus Capital and Lake Bleu Capital. Read more